NKTX - Nkarta Inc
Nkarta Inc Logo

NKTX - Nkarta Inc

https://www.nkartatx.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
As of 2025-09-10 (Snapshot)

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.

52W High
$6.63
52W Low
$1.31
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.77
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
0.95
EV/Revenue (<3 favorable)
1000000.00
P/S (TTM) (<3 favorable)
1000000.00
P/B (<3 favorable)
0.45
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
5.02%
Institutions (25–75% balanced)
86.50%
Shares Outstanding
71,024,000
Float
52,511,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
385
Gross Profit (TTM)
-36,220,000
EPS (TTM)
-1.46
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.27%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
-0.0287
Previous
-0.0138
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025